Un-Audited Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek reported weak un-audited results for Q2 FY26 and the half-year ended September 30, 2025, with revenue from operations of just Rs. 5.28 lakhs for the quarter (vs Rs. 5.85 lakhs in Q2 FY25) and Rs. 10.23 lakhs for H1 FY26 (vs Rs. 10.77 lakhs in H1 FY25). Other income collapsed to zero in H1 FY26 from Rs. 69.58 lakhs a year ago, dragging total income down sharply. The company swung to a loss before tax of Rs. 82.21 lakhs in H1 FY26, compared to a profit of Rs. 12.60 lakhs in H1 FY25, resulting in a negative EPS of Rs. (0.11). On the balance sheet, standalone net worth is deeply negative at Rs. (836.90) lakhs, total borrowings stand at around Rs. 1,650 lakhs, while cash is only Rs. 5.63 lakhs. Operating cash flow turned negative at Rs. (5.77) lakhs versus Rs. 119.58 lakhs last year, and finance costs surged to Rs. 50.98 lakhs from Rs. 3.45 lakhs.
Shareholders face continued losses, a negative net worth, shrinking cash, and rising finance costs, all of which point to serious financial stress. Ongoing cases at SAT, the Appellate Tribunal, and NCLT Hyderabad, combined with management's own admission of difficulty in raising fresh funds, heighten going-concern risk and could weigh negatively on the stock.